MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium

Ottawa, Canada and Fleurus, Belgium (ots/PRNewswire) -

- Site to Provide Fluorodeoxyglucose (F-18 FDG) for use inEarlier Detection of Disease and Therapy Management

MDS Nordion, a leading global provider of medical isotopes andradiopharmaceuticals used in molecular medicine, today announced theopening of a facility in Fleurus, Belgium for the production ofFluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positronemission tomography (PET) imaging.

PET imaging produces a three-dimensional image, or picture, offunctional processes in the body, such as brain activity, and is ahighly accurate and effective method of diagnosing disease andmanaging patient therapy. MDS Nordion's new facility will providetimely supply of F-18 FDG to hospitals throughout Belgium, France,The Netherlands, Luxembourg and Germany.

"Customers count on MDS Nordion for leadership, quality productsand customized services," said Steve West, President MDS Nordion."Our investment in this facility further demonstrates our commitmentto address the growing demand for PET diagnostic imaging in targetedEuropean regions, and provides the medical community greater servicefor their future patient care."

The PET imaging market is the most rapidly growing area ofnuclear medicine and procedures. Statistics from a recent MedicalOptions survey indicates PET examinations are on a rapid rise inEurope, and are expected to grow at a compound annual rate ofapproximately 20% through 2012. To help meet increasing demand, thisstate-of-the-art, Good Manufacturing Practice (GMP) productionfacility will have three daily production runs and a customer serviceteam available 24 hours a day, seven days a week.

"PET imaging is effective because it allows early detection oftumours, as well as assessment of therapeutic strategies," saidProfessor Roland Hustinx, Nuclear Medicine Department, CHU -Universite de Liege. "In particular, MDS Nordion's new facility willprovide another source of supply of F-18 FDG to existing and newmedical facilities, thereby increasing the ability of health-carepractitioners to conduct this critical type of imaging."

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader inproviding medical isotopes for molecular and diagnostic imaging,radiotherapeutics and sterilization technologies for medical productsthat benefit the lives of millions of people in more than 50countries around the world. MDS Nordion's products and services areused on a daily basis by pharmaceutical and biotechnology companies,medical-device manufacturers, hospitals, clinics and researchlaboratories. Find out more at http://www.mdsnordion.com

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences companythat provides market-leading products and services that our customersneed for the development of drugs, and the diagnosis and treatment ofdisease. We are a leading global provider of pharmaceutical contractresearch, medical isotopes for molecular imaging, radiotherapeutics,and analytical instruments. MDS has more than 5,000 highly skilledpeople in 29 countries. Find out more at http://www.mdsinc.com.

ots Originaltext: MDSIm Internet recherchierbar: http://www.presseportal.de

Contact:CONTACT MDS Nordion: MEDIA: Shelley Maclean, +1-613-291-3689, shelley.maclean@mdsinc.com; VPR Consult: Carl Bosteels, +32-473-68-28-50, carl.bosteels@vprconsult.be; INVESTORS: Kim Lee, +1-416-213-4721, kim.lee@mdsinc.com


Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium